Rajneesh Nath, MD, medical oncologist at the Banner MD Anderson Cancer Center, discusses early results from the phase 3 SIERRA trial investigating the efficacy of Iomab-B and protocol-specified…
Anna C. Pavlick, DO, director of High Reliability Organization Initiatives and co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, overviews next generation MEK and…
Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory…
In this interview, Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program –…
By composing a systematic review of randomized clinical trials of patients with advanced melanoma, researchers were able to demonstrate that the risk for immune-related adverse effects (irAEs) is…
Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before…
Jessica Bauman, MD, assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, Temple Health, shares details regarding different RET-fusion mutations in non-small cell lung cancer…
In this panel discussion excerpt, Adam M. Brufsky, MD, PhD, of the University of Pittsburgh and Kashyap Patel, MD, of Carolina Blood and Cancer Care, discuss the role…
Based on results from an earlier study led by Dr Isamu Okamoto of the Graduate School of Medical Sciences at Kyushu University in Fukuoka, Japan that found progression-free…
In this video interview, Jonathan W. Goldman, MD, a health sciences clinical instructor in the Department of Medicine at the Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics…